Future direction of renal positron emission tomography

Seminars in Nuclear Medicine

Volumn 36, Issue 1, 2006, Pages 36-50

  Szabo, Zsolt ^a,b   Xia, Jinsong ^a   Mathews, William B ^a   Brown, Phillip R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 7 [2 (2 CARBOXYPROPYL) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE 6 CARBOXYLIC ACID; AMMONIA N 13; ANGIOTENSIN 1 RECEPTOR; ANION TRANSPORT PROTEIN; CARBON 11; CARRIER PROTEIN; CATION TRANSPORT PROTEIN; COBALT 55; COBALT EDETATE; COPPER 62; COPPER 64; DIPEPTIDYL CARBOXYPEPTIDASE; FLUORINE 18; FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; GALLIUM EDETATE GA 68; GLUCOSE TRANSPORTER; IODINE 125; MICROSPHERE; NITROGEN 13; OXYGEN 15; PEPTIDE TRANSPORTER 1; PEPTIDE TRANSPORTER 2; RADIOISOTOPE; RADIOLIGAND; RAS PROTEIN; RUBIDIUM 82; SODIUM GLUCOSE COTRANSPORTER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE KIDNEY TUBULE NECROSIS; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; ATROPHY; BIOARTIFICIAL ORGAN; BLOOD FLOW; CELL PROLIFERATION; COMPUTER; COMPUTER PROGRAM; CYCLOTRON; DRUG HALF LIFE; FIBROSING ALVEOLITIS; FILTER; GENE TARGETING; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HUMAN; HYPOXIA; IMAGING; KIDNEY BLOOD FLOW; KIDNEY CANCER; KIDNEY DISEASE; KIDNEY TUBULE; MOLECULAR PROBE; NONHUMAN; OBSTRUCTIVE UROPATHY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RENOVASCULAR DISEASE; REPORTER GENE; RESTENOSIS; REVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; URETER OBSTRUCTION; VASCULAR ENDOTHELIUM;

FORECASTING; HUMANS; KIDNEY; KIDNEY DISEASES; PHYSICIAN'S PRACTICE PATTERNS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; RADIOISOTOPE RENOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 28844502019     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2005.08.003     Document Type: Review

References (119)

1. S.M. Hewitt, J. Dear, R.A. Star Discovery of protein biomarkers for renal diseases J Am Soc Nephrol 15 2004 1677 1689
2. C.H. Lorenz, T.A. Powers, C.L. Partain Quantitative imaging of renal blood flow and function Invest Radiol 27 suppl 1992 S109 S114
3. J.C. Romero, L.O. Lerman Novel noninvasive techniques for studying renal function in man Semin Nephrol 20 2000 456 462
4. D.W. Townsend Physical principles and technology of clinical PET imaging Ann Acad Med Singapore 33 2004 133 145
5. M.S. Judenhofer, B.J. Pichler, S.R. Cherry Evaluation of high performance data acquisition boards for simultaneous sampling of fast signals from PET detectors Phys Med Biol 50 2005 29 44
6. G. Kontaxakis, L.G. Strauss, T. Thireou Iterative image reconstruction for clinical PET using ordered subsets, median root prior, and a web-based interface Mol Imaging Biol 4 2002 219 231
7. F. Gutman, I. Gardin, N. Delahaye Optimisation of the OS-EM algorithm and comparison with FBP for image reconstruction on a dual-head camera a phantom and a clinical 18F-FDG study Eur J Nucl Med Mol Imaging 30 2003 1510 1519
8. P. Koepfli, T.F. Hany, C.A. Wyss CT attenuation correction for myocardial perfusion quantification using a PET/CT hybrid scanner J Nucl Med 45 2004 537 542
9. R. Kaatee, F.J. Beek, E.E. de Lange Renal artery stenosis detection and quantification with spiral CT angiography versus optimized digital subtraction angiography Radiology 205 1997 121 127
10. T.S. Kim, J.W. Chung, J.H. Park Renal artery evaluation comparison of spiral CT angiography to intra-arterial DSA J Vasc Interv Radiol 9 1998 553 559
11. R.C. Carlos, D.A. Axelrod, J.H. Ellis Incorporating patient-centered outcomes in the analysis of cost-effectiveness imaging strategies for renovascular hypertension AJR Am J Roentgenol 181 2003 1653 1661
12. N.M. Alpert, C.A. Rabito, D.J. Correia Mapping of local renal blood flow with PET and H(2)(15)O J Nucl Med 43 2002 470 475
13. E.J. Fine, Y. Li, M.D. Blaufox Parenchymal mean transit time analysis of 99mTc-DTPA captopril renography J Nucl Med 41 2000 1627 1631
14. Z. Szabo, H. Vosberg, C.A. Sondhaus, L.E. Feinendegen Model identification and estimation of organ-function parameters using radioactive tracers and the impulse-response function Eur J Nucl Med 11 1985 265 274
15. G. Torsello, Z. Szabo, H. Vosberg Experimental studies on renal transfer function. Effects of renal artery stenosis and occlusion Edizioni Minerva Medica 1985 125 127
16. M. Yamashita, T. Inaba, Y. Kawase Quantitative measurement of renal function using Ga-68-EDTA Tohoku J Exp Med 155 1988 207 208
17. A. Gjedde Compartmental analysis H.N. Wagner Jr Z. Szabo W.J. Buchanan Principles of Nuclear Medicine 1995 Saunders Philadelphia 451 461
18. J. Logan Graphical analysis of PET data applied to reversible and irreversible tracers Nucl Med Biol 27 2000 661 670
19. E.U. Nitzsche, Y. Choi, D. Killion Quantification and parametric imaging of renal cortical blood flow in vivo based on Patlak graphical analysis Kidney Int 44 1993 985 996
20. A. Gjedde, D.F. Wong, H.N. Wagner Transient analysis of irreversible and reversible tracer binding in human brain L. Battistin F. Gerstenbrand PET and NMR New Perspectives in Neuroimaging and in Clinical Neurochemistry 1985 Alan R: Liss, Inc New York 223 235
21. C.S. Patlak, R.G. Blasberg, J.D. Fenstermacher Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data J Cereb Blood Flow Metab 3 1983 1 7
22. Z. Szabo, P.F. Kao, H.D. Burns Investigation of angiotensin II/AT1 receptors with carbon-11-L-159, 884 A selective AT1 antagonist J Nucl Med 39 1998 1209 1213
23. G.D. Hutchins What is the best approach to quantify myocardial blood flow with pet? J Nucl Med 42 2001 1183 1184
24. N.A. Mullani, R.D. Ekas, S. Marani Feasibility of measuring first pass extraction and flow with rubidium-82 in the kidneys Am J Physiol Imaging 5 1990 133 140
25. N. Tamaki, C.A. Rabito, N.M. Alpert Serial analysis of renal blood flow by positron tomography with rubidium-82 Am J Physiol 251 1986 H1024 H1030
26. H. Young, P. Carnochan, J. Zweit Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model Eur J Nucl Med 21 1994 336 341
27. M.E. Shelton, M.A. Green, C.J. Mathias Assessment of regional myocardial and renal blood flow with copper-PTSM and positron emission tomography Circulation 82 1990 990 997
28. H. Young, P. Carnochan, J. Zweit R: Tissue blood flow estimation with copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) and PET J Nucl Biol Med 38 suppl 1 2002 89 91
29. D. Killion, E. Nitzsche, Y. Choi Positron emission tomography a new method for determination of renal function J Urol 150 1993 1064 1068
30. P. Goethals, A. Volkaert, C. Vandewielle 55Co-EDTA for renal imaging using positron emission tomography (PET) a feasibility study Nucl Med Biol 27 2000 77 81
31. G. Karanikas, A. Becherer, K. Wiesner ACE inhibition is superior to angiotensin receptor blockade for renography in renal artery stenosis Eur J Nucl Med Mol Imaging 29 2002 312 318
32. J.H. Clorius, T. Hupp, I. Zuna The exercise renogram and its interpretation J Nucl Med 38 1997 1146 1151
33. M. Imanishi, M. Yano, M. Okumura Aspirin renography in diagnosis of unilateral renovascular hypertension Hypertens Res 21 1998 209 213
34. P. Shreve, P.C. Chiao, H.D. Humes Carbon-11-acetate PET imaging in renal disease J Nucl Med 36 1995 1595 1601
35. N. Oyama, T.R. Miller, F. Dehdashti 11C-acetate PET imaging of prostate cancer detection of recurrent disease at PSA relapse J Nucl Med 44 2003 549 555
36. J. Kotzerke, B.G. Volkmer, G. Glatting Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer Nuclearmedizin 42 2003 25 30
37. M.A. Seltzer, S.A. Jahan, R. Sparks Radiation dose estimates in humans for (11)C-acetate whole-body PET J Nucl Med 45 2004 1233 1236
38. N.B. Nabulsi, D.E. Smith, M.R. Kilbourn [(11)C]Glycylsarcosine synthesis and in vivo evaluation as a PET tracer of PepT2 transporter function in kidney of PepT2 null and wild-type mice Bioorg Med Chem 13 2005 2993 3001
39. H.K. Han, G.L. Amidon Targeted prodrug design to optimize drug delivery AAPS PharmSci 2 2000 E6
40. T. Terada, K. Inui Peptide transporters Structure, function, regulation and application for drug delivery Curr Drug Metab 5 2004 85 94
41. C.U. Nielsen, B. Brodin Di/tri-peptide transporters as drug delivery targets Regulation of transport under physiological and patho-physiological conditions Curr Drug Targets 4 2003 373 388
42. S. Theis, I. Knutter, B. Hartrodt Synthesis and characterization of high affinity inhibitors of the H+/peptide transporter PEPT2 J Biol Chem 277 2002 7287 7292
43. A.K. Padhy, K.K. Solanki, J. Bomanji Clinical evaluation of 99mTc diaminocyclohexane, a renal tubular agent with cationic transport results in healthy human volunteers Nephron 65 1993 294 298
44. D. Wild, H.R. Macke, B. Waser 68Ga-DOTANOC a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5 Eur J Nucl Med Mol Imaging 32 2005 724
45. S. Prakash, M.J. Went, P.J. Blower Cyclic and acyclic polyamines as chelators of rhenium-186 and rhenium-188 for therapeutic use Nucl Med Biol 23 1996 543 549
46. T.M. Jones-Wilson, K.A. Deal, C.J. Anderson The in vivo behavior of copper-64-labeled azamacrocyclic complexes Nucl Med Biol 25 1998 523 530
47. J. Yoo, D.E. Reichert, J. Kim A potential Dubin-Johnson syndrome imaging agent synthesis, biodistribution, and microPET imaging Mol Imaging 4 2005 18 29
48. C.C. Paulusma, M. Kool, P.J. Bosma A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome Hepatology 25 1997 1539 1542
49. X. Sun, J. Kim, A.E. Martell In vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands Nucl Med Biol 31 2004 1051 1059
50. C.W. Heilig, F.C. Brosius III, D.N. Henry Glucose transporters of the glomerulus and the implications for diabetic nephropathy Kidney Int Suppl 60 1997 S91 S99
51. E.M. Wright Renal Na(+)-glucose cotransporters Am J Physiol Renal Physiol 280 2001 F10 F18
52. G.M. Bormans, G. Van Oosterwyck, T.J. de Groot Synthesis and biologic evaluation of (11)c-methyl-d-glucoside, a tracer of the sodium-dependent glucose transporters J Nucl Med 44 2003 1075 1081
53. T.J. de Groot, M. Veyhl, C. Terwinghe Synthesis of 18F-fluoroalkyl-beta- D-glucosides and their evaluation as tracers for sodium-dependent glucose transporters J Nucl Med 44 2003 1973 1981
54. K. Shirota, Y. Kato, K. Suzuki, Y. Sugiyama Characterization of novel kidney-specific delivery system using an alkylglucoside vector J Pharmacol Exp Ther 299 2001 459 467
55. D.R. Hwang, W.C. Eckelman, C.J. Mathias Positron-labeled angiotensin-converting enzyme (ACE) inhibitor fluorine-18-fluorocaptopril. Probing the ACE activity in vivo by positron emission tomography J Nucl Med 32 1991 1730 1737
56. J. Markham, T.J. McCarthy, M.J. Welch In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. I: Theory and error analysis J Appl Physiol 78 1995 1158 1168
57. D.P. Schuster, T.J. McCarthy, M.J. Welch In vivo measurements of pulmonary angiotensin-converting enzyme kinetics. II: Implementation and application J Appl Physiol 78 1995 1169 1178
58. M. Matarrese, A. Salimbeni, E.A. Turolla 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat Bioorg Med Chem 12 2004 603 611
59. A. Akcay, S. Sezer, F.N. Ozdemir Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction Transplantation 78 2004 892 898
60. E. Kaschina, T. Unger Angiotensin AT1/AT2 receptors regulation, signalling and function Blood Press 12 2003 70 88
61. G. Nickenig, K. Strehlow, J. Roeling Salt induces vascular AT1 receptor overexpression in vitro and in vivo Hypertension 31 1998 1272 1277
62. K. Strehlow, S. Wassmann, M. Bohm Angiotensin AT1 receptor over-expression in hypercholesterolaemia Ann Med 32 2000 386 389
63. C.P. Sodhi, Y.S. Kanwar, A. Sahai Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells Am J Physiol Heart Circ Physiol 284 2003 H846 H852
64. E.C. Dumont, S. Rafrafi, S. Laforest Involvement of central angiotensin receptors in stress adaptation Neuroscience 93 1999 877 884
65. Z. Wu, C. Maric, D. Roesch Estrogen regulates adrenal angiotensin type 1 receptors by modulating AT1 receptor translation Endocrinology 144 2003 3251 3261
66. L.M. Harrison-Bernard, I.H. Schulman, L. Raij Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity Hypertension 42 2003 1157 1163
67. G. Nickenig, J. Roling, K. Strehlow Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms Circulation 98 1998 2453 2460
68. G. Nickenig, M. Bohm Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia Eur J Med Res 2 1997 285 289
69. A. Aneja, F. El Atat, S.I. McFarlane Hypertension and obesity Recent Prog Horm Res 59 2004 169 205
70. A. Prasad, A.A. Quyyumi Renin-angiotensin system and angiotensin receptor blockers in the metabolic syndrome Circulation 110 2004 1507 1512
71. J.R. Ortlepp, J. Breuer, F. Eitner Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia Eur J Pharmacol 436 2002 145 150
72. S. Julius, S.E. Kjeldsen, M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial Lancet 363 2004 2022 2031
73. B. Chertin, U. Rolle, S. Cascio Upregulation of angiotensin II receptors in reflux nephropathy J Pediatr Surg 37 2002 251 255
74. P.F. Mento, M.E. Pica, J. Hilepo Increased expression of glomerular AT1 receptors in rats with myocardial infarction Am J Physiol 275 1998 H1247 H1253
75. J.G. Modrall, M.J. Quinones, J.H. Frankhouse Upregulation of angiotensin II type 1 receptor gene expression in chronic renovascular hypertension J Surg Res 59 1995 135 140
76. G. Nickenig Central role of the AT(1)-receptor in atherosclerosis J Hum Hypertens 16 suppl 2002 S26 S33
77. S.E. Kim, U. Scheffel, Z. Szabo In vivo labeling of angiotensin II receptors with a carbon-11-labeled selective nonpeptide antagonist J Nucl Med 37 1996 307 311
78. W.B. Mathews, S.E. Yoo, S.H. Lee A novel radioligand for imaging the AT1 angiotensin receptor with PET Nucl Med Biol 31 2004 571 574
79. Z. Szabo, R.C. Speth, P.R. Brown Use of positron emission tomography to study AT1 receptor regulation in vivo J Am Soc Nephrol 12 2001 1350 1358
80. R.E. Gibson, H.T. Beauchamp, C. Fioravanti Receptor binding radiotracers for the angiotensin II receptor radioiodinated [Sar1, Ile8]Angiotensin II Nucl Med Biol 21 1994 593 600
81. T.K. Owonikoko, M.E. Fabucci, P.R. Brown In vivo investigation of estrogen regulation of adrenal and renal angiotensin (AT1) receptor expression by PET J Nucl Med 45 2003 94 100
82. T.L. Goodfriend Angiotensin receptors History and mysteries Am J Hypertens 13 2000 442 449
83. M. de Gasparo, K.J. Catt, T. Inagami International union of pharmacology. XXIII: The angiotensin II receptors Pharmacol Rev 52 2000 415 472
84. 11C]L-159, 884 a radiolabelled, nonpeptide angiotensin II antagonist that is useful for angiotensin II, AT1 receptor imaging Appl Radiat Isotopes 47 1996 211 218
85. K.W. Hong, C.D. Kim, S.H. Lee The in vitro pharmacological profile of KR31080, a nonpeptide AT1 receptor antagonist Fundam Clin Pharmacol 12 1998 64 69
86. B.H. Lee, H.W. Seo, K.J. Kwon In vivo pharmacologic profile of SK-1080, an orally active nonpeptide AT1-receptor antagonist J Cardiovasc Pharmacol 33 1999 375 382
87. T.K. Owonikoko, M.E. Fabucci, P.R. Brown In vivo investigation of estrogen regulation of adrenal and renal angiotensin AT1 receptor expression by PET J Nucl Med 45 2003 94 100
88. A.C. Guyton, T.G. Coleman, R.D. Manning Some problems and solutions for modeling overall cardiovascular regulation Mathematical Biosci 72 1984 141 155
89. W.P. Anderson, D.E. Ramsey, M. Takata Development of hypertension from unilateral renal artery stenosis in conscious dogs Hypertension 16 1990 441 451
90. Y. Tsuji, D.A. Goldfarb, Z. Masaki Patterns of renal function in hypertension due to unilateral renal artery occlusion Clin Exp Hypertens A 14 1992 1067 1081
91. P.J. Admiraal, A.H. Danser, M.S. Jong Regional angiotensin II production in essential hypertension and renal artery stenosis Hypertension 21 1993 173 184
92. M. Mai, K.F. Hilgers, J. Wagner Expression of angiotensin-converting enzyme in renovascular hypertensive rat kidney Hypertension 25 1995 674X 678X
93. J.A. Haefliger, G. Bergonzelli, G. Waeber Renin and angiotensin II receptor gene expression in kidneys of renal hypertensive rats Hypertension 26 1995 733 737
94. B.M. Wilkes, I. Pion, S. Sollott Intrarenal renin-angiotensin system modulates glomerular angiotensin receptors in the rat Am J Physiol 254 1988 F345 F350
95. X.Y. Lu, X.M. Li, L.Y. Li Variation of intrarenal angiotensin II and angiotensin II receptors by acute renal ischemia in the aged rat Renal Failure 18 1996 19 29
96. V. Regitz-Zagrosek, M. Neuss, J. Holzmeister Molecular biology of angiotensin receptors and their role in human cardiovascular disease J Mol Med 74 1996 233 251
97. C.B. Ernst, M.E. Daugherty, T.A. Kotchen Relatonship between collateral development and renin in experimental renal artery stenosis Surgery 80 1976 252 258
98. C. Llorens-Cortes, B. Greenberg, H. Huang Tissular expression and regulation of type 1 angiotensin II receptor subtypes by quantitative reverse transcriptase-polymerase chain reaction analysis Hypertension 24 1994 538 548
99. T. Unger The role of the renin-angiotensin system in the development of cardiovascular disease Am J Cardiol 89 2002 3A 9A
100. B. Schieffer, E. Schieffer, D. Hilfiker-Kleiner Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques potential implications for inflammation and plaque instability Circulation 101 2000 1372 1378
101. A.J. Pantuck, F. Berger, A. Zisman CL1-SR39 A noninvasive molecular imaging model of prostate cancer suicide gene therapy using positron emission tomography J Urol 168 2002 1193 1198
102. S.C. Textor Ischemic nephropathy Where are we now? J Am Soc Nephrol 15 2004 1974 1982
103. A. Gerhard, J. Schwarz, R. Myers Evolution of microglial activation in patients after ischemic stroke a [11C](R)-PK11195 PET study Neuroimage 24 2005 591 595
104. A. Jemal, R.C. Tiwari, T. Murray Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
105. A.J. Pantuck, A. Zisman, A.S. Belldegrun The changing natural history of renal cell carcinoma J Urol 166 2001 1611 1623
106. W.H. Chow, S.S. Devesa, J.L. Warren Rising incidence of renal cell cancer in the United States JAMA 281 1999 1628 1631
107. D. Sorger, M. Patt, P. Kumar [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO) A comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors Nucl Med Biol 30 2003 317 326
108. J.S. Rasey, Z. Grunbaum, S. Magee Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells Radiat Res 111 1987 292 304
109. J.S. Rasey, W.J. Koh, M.L. Evans Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole A pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
110. W.J. Koh, J.S. Rasey, M.L. Evans Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole Int J Radiat Oncol Biol Phys 22 1992 199 212
111. Y. Fujibayashi, H. Taniuchi, Y. Yonekura A Copper-62-ATSM a new hypoxia imaging agent with high membrane permeability and low redox potential J Nucl Med 38 1997 1155 1160
112. T. Gronroos, O. Eskola, K. Lehtio Pharmacokinetics of [18F]FETNIM A potential marker for PET J Nucl Med 42 2001 1397 1404
113. S.M. Evans, A.V. Kachur, C.Y. Shiue Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1 J Nucl Med 41 2000 327 336
114. J.G. Rajendran, D.C. Wilson, E.U. Conrad [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas correlation of hypoxia, metabolism and VEGF expression Eur J Nucl Med Mol Imaging 30 2003 695 704
115. W.R. Dolbier Jr, A.R. Li, C.J. Koch [18F]-EF5, a marker for PET detection of hypoxia Synthesis of precursor and a new fluorination procedure Appl Radiat Isotopes 54 2001 73 80
116. B endothelin receptor antagonist J Pharmacol Exp Ther 289 1999 1262 1270
117. 11C]L-735, 037 Studies in mice and a dog J Nucl Med 42 2001 1274 1280
118. X. Chen, M. Tohme, R. Park Micro-PET imaging of alphavbeta3-integrin expression with 18F-labeled dimeric RGD peptide Mol Imaging 3 2004 96 104
119. R. Haubner, W.A. Weber, A.J. Beer Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD PLoS Med 2 2005 e70